Crescent Biopharma vs Longeveron
Crescent Biopharma is the larger business, with $10.8m of revenue in fiscal 2025 against $1.2m for Longeveron (9.0 times as much). Crescent Biopharma grew faster (108340.0% against -49.9%). Crescent Biopharma kept more of each dollar of sales as profit: a net margin of -1419.6% against -1893.6%. Crescent Biopharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Crescent BiopharmaCBIO, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $10.8m | $1.2m |
| Revenue growth | 108340.0% | -49.9% |
| Net income | −$154m | −$22.7m |
| Operating margin | -1407.5% | -1942.2% |
| Net margin | -1419.6% | -1893.6% |
| Return on equity | -127.5% | -164.7% |
| Free cash flow | −$72.5m | −$18.9m |
| Cash | $213m | $4.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 44 | 37 |
| Market value | $364m | $55.5m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 2 buys, 16 sales | 0 buys, 0 sales |